Red cell mass measurement in patients with clinically suspected diagnosis of polycythemia vera or essential thrombocythemia

被引：43

作者：

Alvarez-Larran, Alberto ^{[1
]}

Ancochea, Agueda ^{[1
]}

Angona, Anna ^{[1
]}

Pedro, Carme ^{[1
]}

Garcia-Pallarols, Francesc ^{[1
]}

Martinez-Aviles, Luz ^{[2
]}

Bellosillo, Beatriz ^{[2
]}

Besses, Carlos ^{[1
]}

机构：

[1] Univ Pompeu Fabra, Univ Autonoma Barcelona, Hosp del Mar, IMIM,Hematol Dept, Barcelona 08003, Spain

[2] Univ Pompeu Fabra, Univ Autonoma Barcelona, Hosp del Mar, IMIM,Pathol Dept, Barcelona 08003, Spain

来源：

HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2012年 / 97卷 / 11期

关键词：

polycythemia vera; essential thrombocythemia; red cell mass; hemoglobin; hematocrit; RISK ESSENTIAL THROMBOCYTHEMIA; EXPERT PANEL; MYELOFIBROSIS; CRITERIA;

D O I：

10.3324/haematol.2012.067348

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The cut off for hemoglobin or hematocrit that indicates the need for an isotopic red cell mass study was investigated in 179 patients with a presumptive diagnosis of polycythemia vera or essential thrombocythemia. Hematocrit showed better diagnostic accuracy than hemoglobin. Hemoglobin over 18.5 g/dL in males or over 16.5 g/dL in females showed a high specificity indicating that red cell mass study could be avoided in such cases, but it showed low sensitivity leading to 46% false negatives. The best value of hematocrit to indicate a red cell mass study was 0.50 L/L in males (specificity 75%, sensitivity 87.5%) and 0.48 L/L in females (specificity 73%, sensitivity 94%). Lowering the hematocrit threshold to 0.48 L/L in males increased sensitivity up to 95%. A red cell mass study should be performed in patients with suspected diagnosis of essential thrombocythemia or polycythemia vera and with hematocrit between 0.48 L/L and 0.52 L/L.

引用

页码：1704 / 1707

页数：4

共 17 条

[1] Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia [J].

Alvarez-Larran, Alberto ;

Cervantes, Francisco ;

Pereira, Arturo ;

Arellano-Rodrigo, Eduardo ;

Perez-Andreu, Virginia ;

Hernandez-Boluda, Juan-Carlos ;

Ayats, Ramon ;

Salvador, Carlos ;

Muntanola, Ana ;

Bellosillo, Beatriz ;

Vicente, Vicente ;

Hernandez-Nieto, Luis ;

Burgaleta, Carmen ;

Xicoy, Blanca ;

Besses, Carlos .

BLOOD, 2010, 116 (08) :1205-1210

[2] Postpolycythaemic myelofibrosis: frequency and risk factors for this complication in 116 patients [J].

Alvarez-Larran, Alberto ;

Bellosillo, Beatriz ;

Martinez-Aviles, Luz ;

Saumell, Silvia ;

Salar, Antonio ;

Abella, Eugenia ;

Gimeno, Eva ;

Serrano, Sergi ;

Florensa, Lourdes ;

Sanchez, Blanca ;

Pedro, Carmen ;

Besses, Carles .

BRITISH JOURNAL OF HAEMATOLOGY, 2009, 146 (05) :504-509

[3] Philadelphia-Negative Classical Myeloproliferative Neoplasms: Critical Concepts and Management Recommendations From European LeukemiaNet [J].

Barbui, Tiziano ;

Barosi, Giovanni ;

Birgegard, Gunnar ;

Cervantes, Francisco ;

Finazzi, Guido ;

Griesshammer, Martin ;

Harrison, Claire ;

Hasselbalch, Hans Carl ;

Hehlmann, Rudiger ;

Hoffman, Ronald ;

Kiladjian, Jean-Jacques ;

Kroeger, Nicolaus ;

Mesa, Ruben ;

McMullin, Mary F. ;

Pardanani, Animesh ;

Passamonti, Francesco ;

Vannucchi, Alessandro M. ;

Reiter, Andreas ;

Silver, Richard T. ;

Verstovsek, Srdan ;

Tefferi, Ayalew .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (06) :761-770

[4]

Berk PD., 1995, POLYCYTHEMIA VERA MY, P166

[5] Classification of myeloproliferative disorders in the JAK2 era: is there a role for red cell mass? [J].

Cassinat, B. ;

Laguillier, C. ;

Gardin, C. ;

de Beco, V. ;

Burcheri, S. ;

Fenaux, P. ;

Chomienne, C. ;

Kiladjian, J-J .

LEUKEMIA, 2008, 22 (02) :452-453

[6] Myelofibrosis with myeloid metaplasia following essential thrombocythaemia:: actuarial probability, presenting characteristics and evolution in a series of 195 patients [J].

Cervantes, F ;

Alvarez-Larrán, A ;

Talarn, C ;

Gómez, M ;

Montserrat, E .

BRITISH JOURNAL OF HAEMATOLOGY, 2002, 118 (03) :786-790

[7] Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia [J].

Harrison, CN ;

Campbell, PJ ;

Buck, G ;

Wheatley, K ;

East, CL ;

Bareford, D ;

Wilkins, BS ;

van der Walt, JD ;

Reilly, JT ;

Grigg, AP ;

Revell, P ;

Woodcock, BE ;

Green, AR ;

Pearson, TC ;

Conneally, E ;

Crawley, C ;

Cross, NCP ;

Hall, G ;

Hunt, B ;

Lucas, G ;

Ludlam, C ;

McMullin, MF ;

Oscier, D ;

Radia, D ;

Reilly, JT ;

Robinson, G ;

Culligan, DJ ;

Tighe, J ;

Watson, HG ;

Warren, AJ ;

Awaad, MO ;

Obeid, D ;

Cuthbert, RJG ;

Kyle, A ;

Chan-Lam, D ;

Paul, B ;

Cuthbert, RJG ;

McMullin, MF ;

Morris, TCM ;

Johnson, RJ ;

Fegan, C ;

Milligan, DW ;

Galloway, MJ ;

Williamson, PJ ;

Newton, LJ ;

Williams, AT ;

Abboudi, Z ;

Ryan, K ;

Lush, R ;

Blundell, E .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (01) :33-45

[8] An elevated venous haemoglobin concentration cannot be used as a surrogate marker for absolute erythrocytosis: a study of patients with polycythaemia vera and apparent polycythaemia [J].

Johansson, PL ;

Safai-Kutti, S ;

Kutti, J .

BRITISH JOURNAL OF HAEMATOLOGY, 2005, 129 (05) :701-705

[9] Inapparent polycythemia vera: An unrecognized diagnosis [J].

Lamy, T ;

Devillers, A ;

Bernard, M ;

Moisan, A ;

Grulois, I ;

Drenou, B ;

Amiot, L ;

Fauchet, R ;

LePrise, PY .

AMERICAN JOURNAL OF MEDICINE, 1997, 102 (01) :14-20

[10] Serum erythropoietin values in erythrocytoses and in primary thrombocythaemia [J].

Messinezy, M ;

Westwood, NB ;

El-Hemaidi, I ;

Marsden, JT ;

Sherwood, RS ;

Pearson, TC .

BRITISH JOURNAL OF HAEMATOLOGY, 2002, 117 (01) :47-53

← 1 2 →